Biopharma | January 01, 2026
Savara resubmits FDA application for potential treatment in rare lung disease patients
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
Harbour BioMed brings advanced antibody discovery platforms to the table
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
HYMPAVZI’s safety profile was generally favorable
Subscribe To Our Newsletter & Stay Updated
